Orexigen Therapeutics, Inc. (OREX) Announces Valeant Canada will Commercialize Contrave®
Orexigen Therapeutics, Inc. (NASDAQ: OREX) recently announced a distribution agreement between its Orexigen Therapeutics Ireland Ltd. subsidiary and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) regarding the commercialization and distribution of Contrave® (naltrexone HCl / bupropion HCl extended release) in Canada. Per the agreement, Valeant Canada, a subsidiary of Valeant Pharmaceuticals, will be responsible for obtaining Canadian regulatory approval for all the commercialization activities and expenditures. Orexigen will supply Valeant Canada with Contrave tablets at an agreed price, along with potential sales and milestone payments, and expects Valeant to file for Canadian regulatory approval by January 2017. CEO of Orexigen, Mike…







